Sterile Injectable Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type, By Route Of Administration, By Therapeutic Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

"Sterile Injectable Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type, By Route Of Administration, By Therapeutic Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Sterile Injectable Contract Manufacturing Market Growth & Trends

The global sterile injectable contract manufacturing market size is estimated to reach USD 31.92 billion by 2030, growing at a CAGR of 12.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing pipeline and approvals of injectables, growing demand for biologics and biosimilars, rise in investment in research & development activities for the development of novel therapeutics, and increasing demand for cell & gene therapies are the key factors driving the growth of sterile injectable contract manufacturing industry. The market for sterile injectable contract manufacturing is fragmented, with several players having similar technological and processing capabilities.

Contract Manufacturing Organizations (CMOs) with unique capabilities, such as the management of high-potency drugs, are anticipated to dominate the industry. In Europe and the U.S., there are various sterile injectable CMOs with EU GMP and U.S. FDA-approved facilities. Moreover, developing economies such as India and China are anticipated to witness lucrative growth across the forecast period. This is attributable to the increasing demand for injectable sourcing services across these countries. India has over 20 CMOs with EU GMP/U.S. FDA injectable certifications. The Indian sterile injectable contract manufacturing industry is rapidly expanding due to rising demand for outsourcing services from the pharmaceutical giants to emerging markets for cost-effectiveness. Most Indian injectable CMOs have been catering to local demand, but the transition has been evident over the past few years.

The COVID-19 pandemic positively impacted the sterile injectable contract manufacturing industry. This was because of the huge surge in demand for COVID-19 vaccines from 2020 to 2021, as these vaccines are a major part of the injectables industry. In addition, major players in the market are adopting inorganic strategic initiatives such as mergers, acquisitions, and partnerships to enhance their market positions. Furthermore, for the past few years, several companies have focused on penetrating the injectable contract manufacturing industry. For instance, Bridgewest Group, a global private investment firm, announced the launch of a new contract development and manufacturing organization (CDMO) facility focused on sterile injectable drug products.

Sterile Injectable Contract Manufacturing Market Report Highlights

• The large molecule segment accounted for the largest share of 61.3% in 2022. The segment’s growth is driven by increasing demand for large molecule-based therapeutics such as cell & gene therapy, RNA therapy, etc., which constitute a vast portion of large molecules
• Based on therapeutic application, the cancer segment accounted for the largest share of 28.5% in 2022. The growth in the share of this segment is majorly due to the increasing demand for anti-cancer-based injectable therapeutics
• The Subcutaneous (SC) segment is anticipated to register the fastest CAGR of 12.6% during the forecast period. This is because of the high demand for SC injectables globally, owing to their associated benefits while administering vaccines, growth hormones, and insulin
• Biopharmaceutical companies are anticipated to witness the highest CAGR of 12.4% over the forecast period due to the increasing number of biopharmaceutical companies investing in developing novel sterile injectables
• Asia Pacific is anticipated to witness the highest CAGR of 13.1% during the forecast period. This high growth is primarily due to the increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as India and China

Please note The report will be delivered in 4-8 business days upon order notification.